Literature DB >> 19802001

Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.

M Shiota1, A Yokomizo, Y Tada, J Inokuchi, E Kashiwagi, D Masubuchi, M Eto, T Uchiumi, S Naito.   

Abstract

There are few successful therapies for castration-resistant prostate cancer (CRPC). Recently, CRPC has been thought to result from augmented androgen/androgen receptor (AR) signaling pathway, for most of which AR overexpression has been observed. In this study, Twist1, a member of basic helix-loop-helix transcription factors as well as AR was upregulated in response to hydrogen peroxide, and the response to which was abolished by an addition of N-acetyl-L-cysteine and Twist1 knockdown. In addition, castration-resistant LNCaP derivatives and hydrogen peroxide-resistant LNCaP derivatives exhibited a similar phenotype to each other. Then, both castration and AR knockdown increased intracellular reactive oxygen species level. Moreover, Twist1 was shown to regulate AR expression through binding to E-boxes in AR promoter region. Silencing of Twist1 suppressed cell growth of AR-expressing LNCaP cells as well as castration-resistant LNCaP derivatives by inducing cell-cycle arrest at G1 phase and cellular apoptosis. These findings indicated that castration-induced oxidative stress may promote AR overexpression through Twist1 overexpression, which could result in a gain of castration resistance. Modulation of castration-induced oxidative stress or Twist1/AR signaling might be a useful strategy for developing a novel therapeutics in prostate cancer, even in CRPC, which remains dependent on AR signaling by overexpressing AR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802001     DOI: 10.1038/onc.2009.322

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

1.  Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.

Authors:  Wen-Chin Huang; Xiangyan Li; Jian Liu; Jentai Lin; Leland W K Chung
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

2.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.

Authors:  Ankur Sharma; Wen-Shuz Yeow; Adam Ertel; Ilsa Coleman; Nigel Clegg; Chellappagounder Thangavel; Colm Morrissey; Xiaotun Zhang; Clay E S Comstock; Agnieszka K Witkiewicz; Leonard Gomella; Erik S Knudsen; Peter S Nelson; Karen E Knudsen
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 3.  Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.

Authors:  Reem Malek; Hailun Wang; Kekoa Taparra; Phuoc T Tran
Journal:  Cells Tissues Organs       Date:  2017-02-20       Impact factor: 2.481

4.  Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer.

Authors:  Kumar Nikhil; Lei Chang; Keith Viccaro; Max Jacobsen; Callista McGuire; Shakti R Satapathy; Michael Tandiary; Meaghan M Broman; Gregory Cresswell; Yizhou J He; George E Sandusky; Timothy L Ratliff; Dipanjan Chowdhury; Kavita Shah
Journal:  Cancer Lett       Date:  2019-02-01       Impact factor: 8.679

5.  Efficacy of androgen deprivation therapy and the role of oxidative stress.

Authors:  D K Price
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

6.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Xianzeng Hou; Chen Shao; Junjie Li; Ji-Xin Cheng; Shihuan Kuang; Nihal Ahmad; Timothy Ratliff; Xiaoqi Liu
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

7.  A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.

Authors:  Christos E Kyriakopoulos; Elisabeth I Heath; Jens C Eickhoff; Jill Kolesar; Mulusew Yayehyirad; Thomas Moll; George Wilding; Glenn Liu
Journal:  Invest New Drugs       Date:  2016-02-29       Impact factor: 3.850

8.  Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.

Authors:  Jason Boyang Wu; Chen Shao; Xiangyan Li; Qinlong Li; Peizhen Hu; Changhong Shi; Yang Li; Yi-Ting Chen; Fei Yin; Chun-Peng Liao; Bangyan L Stiles; Haiyen E Zhau; Jean C Shih; Leland W K Chung
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

Review 9.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

10.  Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.

Authors:  Masaki Shiota; Akira Yokomizo; Yasuhiro Tada; Junichi Inokuchi; Katsunori Tatsugami; Kentaro Kuroiwa; Takeshi Uchiumi; Naohiro Fujimoto; Narihito Seki; Seiji Naito
Journal:  Mol Endocrinol       Date:  2009-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.